A review of metabolic issues in atypical antipsychotic treatment

Advanced Studies in Medicine

Volumn 4, Issue 10 H, 2004, Pages

  Newcomer, John W ^a   Nasrallah, Henry A ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEPRESSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIPID METABOLISM; LONG TERM CARE; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PREVALENCE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SHORT COURSE THERAPY; SIDE EFFECT; WEIGHT GAIN;

EID: 13244294222     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Newcomer J. Atypical antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. In press.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
3. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999;341:1097-1105.
4. NIH/NHLBI Guidelines. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. Bethesda, Md: National Institutes of Health; 1998. NIH publication 98-4-94.
5. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530-1538.
6. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2002. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003.
7. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
8. Gu K, Cowie C, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care. 1998;21:1138-1145.
9. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
10. NCEP Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143-3421.
11. Reaven G. Syndrome X: 10 years after. Drugs. 1999;58(suppl 1):19-20; discussion 75-82.
12. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
13. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697-701.
14. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97:1095-1102.
15. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71-83.
16. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502-508.
17. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167-181.
18. Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res. 2002;53:925-933.
19. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use [published correction appears in J Affect Disord. 2003;73:301-302]. J Affect Disord. 2002;70:19-26.
20. Chiba M, Suzuki S, Hinokio Y, et al. Tyrosine hydroxylase gene microsatellite polymorphism associated with insu in resistance in depressive disorder. Metabolism. 2000;49:1145-1149.
21. Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism. 2000;49:1255-1260.
22. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand. 1999;100:3-16.
23. Allison DB, Mentore LJ, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
24. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
25. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001;111:716-723.
26. Koller EA, Doraiswany PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-852.
27. Koller EA, Cross JT, Doraiswany PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735-744.
28. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345.
29. Henderson, et al. Arch Gen Psychiatry. Submitted.
30. Masaki T, Chiba S, Yasuda T, et al. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes. 2004;53:2250-2260.
31. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519-526.
32. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359:2086-2087.
33. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand. 2000;101:416-432.
34. Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:69-80.
35. Ardizzone TD, Bradley RJ, Freeman AM III, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 2001;923:82-90.
36. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav. 2003;75:255-260.
37. Elman I, Goldstein DS, Eisenhofer G, et al. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology. 1999;20:29-34.
38. Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol. 1998;21:245-250.
39. Haupf DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62(suppl 27):15-26; discussion 40-41.
40. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124:978-982.
41. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther. 1970;11:883-889.
42. Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenzaine and clopenthixol. Dan Med Bull. 1964;11:182-189.
43. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry. 1997;58:108-111.
44. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom. 2002;71:244-254.
45. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res. 2003;59:49-57.
46. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
47. Lund BC, Perry PJ, Brookd JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58:1172-1176.
48. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920-930.
49. Lambert B, Chou C-H, Chang KY, et al. Assessing the risk of antipsychotic-induced type II diabetes among schizophrenics: a matched case-control study. Eur Neuropsychopharmacol. 2002;12(suppl 3):S307, abstract P.2.126.
50. Citrome L, Jaffe A, Levine J, et al. Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycemics. Eur Neuropsychopharmacol. 2003;13(suppl 4):S306, abstract P.2.063.
51. Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002;22:236-243.
52. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290-296.
53. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry. 2001;62(suppl 23):5-12.
54. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
55. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598-604.
56. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856-865.
57. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999;156:1270-1272.
58. Spivak B, Lamschtein C, Talmon Y, et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol. 1999;22:98-101.
59. Dursun SM, Szemis A, Andrews H, Reveley MA. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci. 1999;24:453-455.
60. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002;63:1148-1155.
61. Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56:104-170.
62. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23:1037-1043.
63. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328-335.
64. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135-1139.
65. Farwell WR, Stump TE, Wang J, et al. Do olanzapine and risperidone cause weight gain and diabetes? Int J Neuropsychopharmacol. 2002;5(suppl 1):S170, abstract P.3.W.049.
66. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325(7358):243.
67. Ebenbichler CF, Laimer M, Eder U, et al. Olanzapine induced insulin resistance: results from a prospective study. J Clin Psychiatry, 2003;64:1430-1439.
68. Glick ID, Romano SJ, Simpson G, et al. Insulin resistance in olanzapine- and ziprasidone-treated patients: results of a double-blind, controlled 6-week trial. Presented at: Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La.
69. Simpson GM, Weiden P, Pigolt T, et al. Ziprasidone versus olanzapine in schizophrenia: 6-month continuation study. Eur Neuropsychopharmacol. 2002;12(suppl 3):S310, abstract P.2.134.
70. Hardy TA, Poole-Hoffmann V, Lu Y, et al. Fasting glucose and lipid changes in patients with schizophrenia treated with olanzapine or ziprasidone. Poster presented at: 42nd Annual Meeting of the American College of Neuropsychopharmacology; December 7-11, 2003; San Juan, Puerto Rico.
71. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with oanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87:2918-2923..
72. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, ar placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab. 2003;88:5875-5880.
73. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59:1021-1026.
74. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60:767-770.
75. Dimelis D, Garyfallos G, Kiouniakis F, et al. Olanzapine versus risperidone: impact on weight gain and blood lipids. Is there any relationship with antipsychotic efficacy? Eur Neuropsychopharmacol. 2002;12(suppl 3):S328, abstract P.2.175.
76. Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-433.
77. Gupta S, Steinmeyer C, Frank B, et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther. 2003;10:348-355.
78. Berry S, Mahmoud R. Improvement of insulin indices after switch from olanzapine to risperidone. Eur Neuropsychopharmacol. 2002;12(suppl 3):S316, abstract P.2.148.
79. Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new-onset diabetes. Biol Psychiatry. 2001;50:148-149.
80. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment [letter]. Psychosomatics. 2000;41:369-370.
81. Mallya A, Chawla P, Boyer SK, DeRosear L. Resolution of hyperglycemia on risperidone discontinuation: a case report [letter]. J Clin Psychiatry. 2002;63:453-454.
82. Wilson DR, D'Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003;59:1-6.
83. Cavazzoni P, Hornbuckle K, Wu J, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United Kingdom. Int J Neuropsychopharmacol. 2002;5(suppl 1):S168, abstract P3.W.043.
84. Ghaeli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy. 1999;19:1099-1101.
85. Hardy T, Sowell E, Marquez E, et al. Cross-sectional comparison of fasting triglycerides in normoglycemic patients with schizophrenia treated with olanzapine, risperidone, or typical antipsychotics. Eur Neuropsychopharmacol. 2003;13(suppl 4):S339, abstract P.2.138.
86. Conley RR, Mahmoud R. A randomized, double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-774.
87. Martin A, L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone treated youths. A retrospective study. Eur Child Adolesc Psychiatry. 2002;11:129-133.
88. Kurt E, Oral ET. Antipsychotics and glucose, insulin, lipids, prolactin, uric acid metabolism in schizophrenia. Eur Neuropsychopharmacol. 2002;12(suppl 3):S276, abstract P.2.049.
89. Sneed KB, Gonzalez EC. Type 2 diabetes mellitus induced by an atypical antipsychotic medication. J Am Board Fam Pract. 2003;16:251-254.
90. Procyshyn RM, Kennedy NB, Marriage S, Wasan KM. Plasma protein and lipoprotein distribution of clozapine. Am J Psychiatry. 2001;158:949-951.
91. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. J Clin Psychiatry. 1999;60:556-557.
92. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369-374.
93. Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia [letter]. J Am Acad Child Adolesc Psychiatry. 2002;41:495-490.
94. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol. 2001;11:415-424.
95. Daniel DG, Zimbroff DL, Patkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999;20:491-505.
96. Cohen S, Fitzgerald B, Okos A, et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry. 2003;64:60-62.
97. Kingsbury SJ, Fayek M, Trufasiu D, et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry. 2001;62:347-349.
98. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone [letter]. Am J Psychiatry. 2002;159:1435.
99. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia [review]. Clin Ther. 2002;24:21-37.
100. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595-600.
101. Weiden PJ, Daniel DG, Leobel AD, et al. Course of weight and metabolic benefits one year after switching to ziprasidone. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-0, 2004; New York, NY
102. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res. 2003;61:123-136.
103. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole versus haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6:325-337.
104. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole far the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64:1048-1050.
105. McQuade R, Jody D, Kujawa M, et al. Long-term weight effects of aripiprazole versus olanzapine Poster presented at: the American Psychiatric Association; May 2003; San Francisco, Calif.
106. Cornblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychopharmacol. 2002;5(suppl 1):S185.
107. McQuade RD, Marcus R, Sanchez R, et al. Aripiprazale versus placebo in acute mania: safety and tolerability pooled analysis. Poster presented at: the 5th International Conference on Bipolar Disorder; June 12-14, 2003; Pittsburgh, Pa.
108. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S5-S10.
109. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
110. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care. 2003;26:3153-3159.
111. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
112. L'Italien GJ. Pharmacoeconomic impact of antipsychotic-induced metabolic events. Prev Med Managed Care. 2003;3(suppl 2):S38-S42.
113. Casey D, L'Italian G, Waldeck R, et al. Metabolic syndrome comparison between oanzapine, aripiprazole and placebo. Poster presented at: the American Psychiatric Association; May 2003; San Francisco, Calif.
114. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia Am J Psychiatry. 2004;161:1334-1349.